AHMED NADIM
President and CEO
AHMED NADIM has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Feb 25, 2026.
On the most recent filing, AHMED NADIM is listed as President and CEO at Cullinan Therapeutics, Inc. Inside the rolling window, AHMED NADIM reported no open-market purchases and 3 open-market sales totaling $518K in CGEM. The largest disclosed transaction in the window is a sale of 16,381 CGEM shares on Feb 20, 2026, worth $223K.
Companies traded
Other insiders at CGEM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$518K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has AHMED NADIM made?
AHMED NADIM has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does AHMED NADIM trade?
AHMED NADIM has filed SEC Form 4 disclosures for 1 company, including CGEM.
When was AHMED NADIM's most recent SEC Form 4 filing?
AHMED NADIM's most recent SEC Form 4 filing on Tracefour is dated Feb 25, 2026.
What is AHMED NADIM's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, AHMED NADIM is listed as President and CEO.
What is AHMED NADIM's total buy and sell value in the current window?
Inside the rolling retention window, AHMED NADIM bought $0 and sold $518K based on SEC Form 4 filings.
What was AHMED NADIM's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 16,381 CGEM shares on 2026-02-20, worth $223K, per SEC Form 4 filings.